Romania
· Delayed Price · Currency is RON Antibiotice Statistics
Total Valuation
Antibiotice has a market cap or net worth of RON 1.39 billion. The enterprise value is 1.53 billion.
| Market Cap | 1.39B |
| Enterprise Value | 1.53B |
Important Dates
The last earnings date was Thursday, April 10, 2025.
| Earnings Date | Apr 10, 2025 |
| Ex-Dividend Date | Sep 25, 2025 |
Share Statistics
Antibiotice has 671.34 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 671.34M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 1.04% |
| Float | 117.94M |
Valuation Ratios
The trailing PE ratio is 14.01.
| PE Ratio | 14.01 |
| Forward PE | n/a |
| PS Ratio | 2.03 |
| PB Ratio | 1.55 |
| P/TBV Ratio | 1.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 15.40 |
| EV / Sales | 2.23 |
| EV / EBITDA | 10.10 |
| EV / EBIT | 14.23 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.08, with a Debt / Equity ratio of 0.16.
| Current Ratio | 2.08 |
| Quick Ratio | 1.32 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 0.93 |
| Debt / FCF | n/a |
| Interest Coverage | 23.69 |
Financial Efficiency
Return on equity (ROE) is 11.40% and return on invested capital (ROIC) is 6.89%.
| Return on Equity (ROE) | 11.40% |
| Return on Assets (ROA) | 5.56% |
| Return on Invested Capital (ROIC) | 6.89% |
| Return on Capital Employed (ROCE) | 10.24% |
| Revenue Per Employee | 508,567 |
| Profits Per Employee | 73,643 |
| Employee Count | 1,350 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.41 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.90% in the last 52 weeks. The beta is 0.11, so Antibiotice's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | +8.90% |
| 50-Day Moving Average | 2.28 |
| 200-Day Moving Average | 2.74 |
| Relative Strength Index (RSI) | 35.65 |
| Average Volume (20 Days) | 198,414 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Antibiotice had revenue of RON 686.57 million and earned 99.42 million in profits. Earnings per share was 0.15.
| Revenue | 686.57M |
| Gross Profit | 452.45M |
| Operating Income | 107.57M |
| Pretax Income | 103.29M |
| Net Income | 99.42M |
| EBITDA | 151.63M |
| EBIT | 107.57M |
| Earnings Per Share (EPS) | 0.15 |
Balance Sheet
The company has 2.68 million in cash and 140.71 million in debt, giving a net cash position of -138.03 million or -0.21 per share.
| Cash & Cash Equivalents | 2.68M |
| Total Debt | 140.71M |
| Net Cash | -138.03M |
| Net Cash Per Share | -0.21 |
| Equity (Book Value) | 897.61M |
| Book Value Per Share | 1.34 |
| Working Capital | 246.07M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 65.90%, with operating and profit margins of 15.67% and 14.48%.
| Gross Margin | 65.90% |
| Operating Margin | 15.67% |
| Pretax Margin | 15.05% |
| Profit Margin | 14.48% |
| EBITDA Margin | 22.09% |
| EBIT Margin | 15.67% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.08, which amounts to a dividend yield of 4.00%.
| Dividend Per Share | 0.08 |
| Dividend Yield | 4.00% |
| Dividend Growth (YoY) | -75.21% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 4.00% |
| Earnings Yield | 7.14% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on May 13, 2013. It was a forward split with a ratio of 1.1819213313.
| Last Split Date | May 13, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1819213313 |
Scores
Antibiotice has an Altman Z-Score of 4.32.
| Altman Z-Score | 4.32 |
| Piotroski F-Score | n/a |